Exhibit 99.1

Pro Forma Unaudited Consolidated Financial Information

     The following unaudited pro forma consolidated financial statements have been prepared from the historical financial statements of Cardo Medical, Inc., as adjusted, to give effect to the sale of substantially all of the assets of the Spine Division, which we refer to as the Spine Asset Sale below. The Spine Asset Sale was consummated on April 4, 2011 pursuant to the Asset Purchase Agreement, dated as of April 4, 2011, entered into by Cardo Medical, Inc., Cardo Medical, LLC (Cardo Medical, Inc. and Cardo Medical, LLC are collectively referred to as the “Sellers”) and Altus Partners, LLC (the “Buyer”) pursuant to which the Sellers agreed to sell substantially all of the assets of the Sellers’ spine division to the Buyer in exchange for cash consideration of $3,000,000. The unaudited pro forma consolidated balance sheet as of December 31, 2010 reflects adjustments as if the Spine Asset Sale had occurred on December 31, 2010. The unaudited pro forma consolidated statement of operations for the year ended December 31, 2010 reflect adjustments as if the Spine Asset Sale had occurred on January 1, 2010.

     The unaudited pro forma consolidated financial statements do not purport to present the financial position or results of operations of Cardo Medical, Inc. had the Spine Asset Sale occurred on the dates specified, nor are they necessarily indicative of the results of operations that may be achieved in the future.

     These unaudited pro forma consolidated financial statements should be read in conjunction with Cardo Medical, Inc.’s historical consolidated financial statements and accompanying notes included in its Form 10-K filed on March 31, 2011.

						Pro Forma
						Adjustment
						Effect of
		December 31,				Spine				Pro Forma
		2010				Asset Sale				Combined
						(unaudited)				(unaudited)
						[A]
(in ‘000s)
Assets
Current assets
Cash		$	127			$	3,000			$	3,127
Accounts receivable, net			413								413
Prepaid expenses and other current assets			99								99
Total current assets			639				3,000				3,639
Assets held for sale			4,765				(713	)			4,052
Deposits			31								31
Total assets		$	5,435			$	2,287			$	7,722
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable and accrued expenses		$	1,656			$				$	1,656
Note payable — Arthrex			—								—
Note payable — related party			300								300
Note payable			200								200
Total liabilities			2,156				—				2,156
Stockholders’ equity
Common stock			230								230
Additional paid-in capital			25,773								25,773
Note receivable from stockholder			(50	)							(50	)
Accumulated deficit			(22,674	)			2,287				(20,387	)
Total stockholders’ equity			3,279				2,287				5,566
Total liabilities and stockholders’ equity		$	5,435			$	2,287			$	7,722

						Pro Forma Adjustment
		Year Ended				Gain on
		December 31,				Spine				Pro Forma
		2010				Asset Sale				Combined
						(unaudited)				(unaudited)
						[A]
(in ‘000s)
Net sales		$	—			$	—			$	—
Cost of sales			—				—				—
Gross profit			—				—				—
Research and development expenses			—				—				—
Selling, general and administrative expenses			583				—				583
Loss from operations			(583	)			—				(583	)
Interest income (expense), net			27				—				27
Loss from continuing operations before income tax provision			(556	)			—				(556	)
Provision for income taxes			—				—				—
Loss from continuing operations			(556	)			—				(556	)
Discontinued operations
Loss from discontinued operations			(10,953	)			—				(10,953	)
Gain on disposal			—				2,287				2,287
Net (loss) income		$	(11,509	)		$	2,287			$	(9,222	)
Basic and diluted (loss) income per share before discontinued operations			(0.00	)			—				(0.00	)
Discontinued operations			(0.05	)			0.01				(0.04	)
Basic and diluted loss per share		$	(0.06	)		$	0.01			$	(0.04	)
Weighted average shares outstanding:
Basic and diluted			230,293,141				230,293,141				230,293,141